Children with eosinophilic esophagitis non-responsive to combination therapy have distinct esophageal transcriptomic and microbiome profile.
Metatranscriptomics
eosinophilic esophagitis
gene expression
immune response
microbiome
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
12 Jul 2024
12 Jul 2024
Historique:
revised:
22
04
2024
received:
05
01
2024
accepted:
03
06
2024
medline:
12
7
2024
pubmed:
12
7
2024
entrez:
12
7
2024
Statut:
aheadofprint
Résumé
A combination of proton-pump inhibitors (PPI) and topical steroids (TS) is used to treat children with eosinophilic esophagitis (EoE). However, a subset of children do not respond to this combination therapy. We aimed to identify the esophageal transcriptional, cell composition, and microbial differences between the non-responders (EoE-PPI-TSnr; n = 7) and responders (EoE-PPI-TSr; n = 7) to the combination therapy for EoE and controls (n = 9) using metatranscriptomics. Differential gene expression analysis was used to identify transcriptional differences, validated using the EoE diagnostic panel (EDP). Deconvolution analysis was performed to identify differences in their cell type composition. Microbiome analysis was conducted from esophageal biopsies RNAseq data, and microbial abundance was correlated with esophageal gene expression. In all, 3164 upregulated and 3154 downregulated genes distinguished EoE-PPI-TSnr from EoE-PPI-TSr. Eosinophilic inflammatory response, cytokine signaling, and collagen formation pathways were significantly upregulated in EoE-PPI-TSnr. There was a 56% overlap in dysregulated genes between EoE-PPI-TSnr and EDP, with a perfect agreement in the directionality of modulation. Eosinophils, dendritic cells (DCs), immature DCs, megakaryocytic-erythroid progenitors, and T helper type 1 cells were significantly higher in EoE-PPI-TSnr. There was no significant difference in microbiome diversity. The relative abundance of Fusobacterium sp. and Acinetobacter sp. notably differed in EoE-PPI-TSnr and correlated with the key pathways. Our results provide critical insights into the molecular, cellular, and microbial factors associated with the lack of response to PPI and TS combination therapy in children with EoE. This study advances our understanding of the pathobiology of EoE while guiding personalized treatment strategies.
Sections du résumé
BACKGROUND
BACKGROUND
A combination of proton-pump inhibitors (PPI) and topical steroids (TS) is used to treat children with eosinophilic esophagitis (EoE). However, a subset of children do not respond to this combination therapy. We aimed to identify the esophageal transcriptional, cell composition, and microbial differences between the non-responders (EoE-PPI-TSnr; n = 7) and responders (EoE-PPI-TSr; n = 7) to the combination therapy for EoE and controls (n = 9) using metatranscriptomics.
METHODS
METHODS
Differential gene expression analysis was used to identify transcriptional differences, validated using the EoE diagnostic panel (EDP). Deconvolution analysis was performed to identify differences in their cell type composition. Microbiome analysis was conducted from esophageal biopsies RNAseq data, and microbial abundance was correlated with esophageal gene expression.
RESULTS
RESULTS
In all, 3164 upregulated and 3154 downregulated genes distinguished EoE-PPI-TSnr from EoE-PPI-TSr. Eosinophilic inflammatory response, cytokine signaling, and collagen formation pathways were significantly upregulated in EoE-PPI-TSnr. There was a 56% overlap in dysregulated genes between EoE-PPI-TSnr and EDP, with a perfect agreement in the directionality of modulation. Eosinophils, dendritic cells (DCs), immature DCs, megakaryocytic-erythroid progenitors, and T helper type 1 cells were significantly higher in EoE-PPI-TSnr. There was no significant difference in microbiome diversity. The relative abundance of Fusobacterium sp. and Acinetobacter sp. notably differed in EoE-PPI-TSnr and correlated with the key pathways.
CONCLUSION
CONCLUSIONS
Our results provide critical insights into the molecular, cellular, and microbial factors associated with the lack of response to PPI and TS combination therapy in children with EoE. This study advances our understanding of the pathobiology of EoE while guiding personalized treatment strategies.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Furuta GT, Katzka DA. Eosinophilic esophagitis. N Engl J Med. 2015;373:1640‐1648.
Navarro P, Arias Á, Arias‐González L, Laserna‐Mendieta EJ, Ruiz‐Ponce M, Lucendo AJ. Systematic review with meta‐analysis: the growing incidence and prevalence of eosinophilic oesophagitis in children and adults in population‐based studies. Aliment Pharmacol Ther. 2019;49:1116‐1125.
Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol. 2011;128:3‐20.e6.
Schoepfer AM, Safroneeva E, Bussmann C, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time‐dependent manner. Gastroenterology. 2013;145:1230‐1236.
Rank MA, Sharaf RN, Furuta GT, et al. Technical review on the management of eosinophilic esophagitis: a report from the AGA institute and the joint task force on allergy‐immunology practice parameters. Gastroenterology. 2020;158:1789‐1810.e15.
Marabotto E, Giannini EG, Zentilin P, et al. Pharmacotherapies in eosinophilic esophagitis: state of the art. Minerva Gastroenterol. 2022;68:69‐76.
Gutiérrez‐Junquera C, Fernández‐Fernández S, Cilleruelo ML, Rayo A, Román E. The role of proton pump inhibitors in the management of pediatric eosinophilic esophagitis. Front Pediatr. 2018;6:119.
Franciosi JP, Mougey EB, Dellon ES, et al. Proton pump inhibitor therapy for eosinophilic esophagitis: history, mechanisms, efficacy, and future directions. J Asthma Allergy. 2022;15:281‐302.
Laserna‐Mendieta EJ, Casabona S, Savarino E, et al. Efficacy of therapy for eosinophilic esophagitis in real‐world practice. Clin Gastroenterol Hepatol. 2020;18:2903‐2911.e4.
Wen T, Dellon ES, Moawad FJ, Furuta GT, Aceves SS, Rothenberg ME. Transcriptome analysis of proton pump inhibitor‐responsive esophageal eosinophilia reveals PPI‐reversible allergic inflammation. J Allergy Clin Immunol. 2015;135:187‐197.
Rochman M, Xie YM, Mack L, et al. Broad transcriptional response of the human esophageal epithelium to proton pump inhibitors. J Allergy Clin Immunol. 2021;147:1924‐1935.
Eluri S, Selitsky SR, Perjar I, et al. Clinical and molecular factors associated with histologic response to topical steroid treatment in patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2019;17:1081‐1088.e2.
Laserna‐Mendieta EJ, FitzGerald JA, Arias‐Gonzalez L, et al. Esophageal microbiome in active eosinophilic esophagitis and changes induced by different therapies. Sci Rep. 2021;11:7113.
Lucendo AJ, de Rezende L, Comas C, Caballero T, Bellón T. Treatment with topical steroids downregulates IL‐5, eotaxin‐1/CCL11, and eotaxin‐3/CCL26 gene expression in eosinophilic esophagitis. Am J Gastroenterol. 2008;103:2184‐2193.
Benitez AJ, Hoffmann C, Muir AB, et al. Inflammation‐associated microbiota in pediatric eosinophilic esophagitis. Microbiome. 2015;3:23.
Park CH, Lee SK. Exploring esophageal microbiomes in esophageal diseases: a systematic review. J Neurogastroenterol Motil. 2020;26:171‐179.
Shakya M, Lo C‐C, Chain PSG. Advances and challenges in Metatranscriptomic analysis. Front Genet. 2019;10:904. doi:10.3389/fgene.2019.00904. https://www.frontiersin.org/articles/
Bikel S, Valdez‐Lara A, Cornejo‐Granados F, et al. Combining metagenomics, metatranscriptomics and viromics to explore novel microbial interactions: towards a systems‐level understanding of human microbiome. Comput Struct Biotechnol J. 2015;13:390‐401.
Zhang X, Li L, Butcher J, Stintzi A, Figeys D. Advancing functional and translational microbiome research using meta‐omics approaches. Microbiome. 2019;7:154.
Busing JD, Buendia M, Choksi Y, Hiremath G, Das SR. Microbiome in eosinophilic esophagitis—metagenomic, Metatranscriptomic, and metabolomic changes: a systematic review. Front Physiol. 2021;12:731034. doi:10.3389/fphys.2021.731034. https://www.frontiersin.org/articles/
Wen T, Rothenberg ME. Clinical applications of the eosinophilic esophagitis diagnostic panel. Front Med (Lausanne). 2017;4:108.
Hiremath G, Locke A, Thomas G, et al. Novel insights into tissue‐specific biochemical alterations in pediatric eosinophilic esophagitis using Raman spectroscopy. Clin Transl Gastroenterol. 2020;11:e00195.
Hiremath G, Shilts MH, Boone HH, et al. The salivary microbiome is altered in children with eosinophilic esophagitis and correlates with disease activity. Clin Transl Gastroenterol. 2019;10:e00039.
Dellon ES, Liacouras CA, Molina‐Infante J, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference. Gastroenterology. 2018;155:1022‐1033.
Hirano I, Moy N, Heckman MG, Thomas CS, Gonsalves N, Achem SR. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. Gut. 2013;62:489‐495.
Rajagopala SV, Bakhoum NG, Pakala SB, et al. Metatranscriptomics to characterize respiratory virome, microbiome, and host response directly from clinical samples. Cell Rep Methods. 2021;1:100091.
Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114‐2120.
Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015;12:357‐360.
Anders S, Pyl PT, Huber W. HTSeq—a python framework to work with high‐throughput sequencing data. Bioinformatics. 2015;31:166‐169.
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA‐seq data with DESeq2. Genome Biol. 2014;15:550.
Kuleshov MV, Jones MR, Rouillard AD, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44:W90‐W97.
Aran D. Cell‐type enrichment analysis of bulk transcriptomes using xCell. In: Boegel S, ed. Bioinformatics for Cancer Immunotherapy: Methods and Protocols. Springer US; 2020:263‐276.
Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18:220.
Gu Z, Hübschmann D. Make interactive complex heatmaps in R. Bioinformatics. 2022;38:1460‐1462.
Sunagawa S, Mende DR, Zeller G, et al. Metagenomic species profiling using universal phylogenetic marker genes. Nat Methods. 2013;10:1196‐1199.
Kruskal WH, Wallis WA. Use of ranks in one‐criterion variance analysis. J Am Stat Assoc. 1952;47:583‐621.
McMurdie PJ, Holmes S. Phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One. 2013;8:e61217.
Arias Á, Lucendo AJ. Molecular basis and cellular mechanisms of eosinophilic esophagitis for the clinical practice. Expert Rev Gastroenterol Hepatol. 2019;13:99‐117.
Davis BP, Rothenberg ME. Mechanisms of disease of eosinophilic esophagitis. Annu Rev Pathol. 2016;11:365‐393.
Press Release. Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE). Accessed April 8, 2024. https://www.sanofi.com/en/media‐room/press‐releases/2024/2024‐01‐25‐19‐30‐00‐2817342
Aceves SS, Dellon ES, Greenhawt M, Hirano I, Liacouras CA, Spergel JM. Clinical guidance for the use of dupilumab in eosinophilic esophagitis: a yardstick. Ann Allergy Asthma Immunol. 2023;130:371‐378.
Subramanian Vignesh K, Deepe GS. Metallothioneins: emerging modulators in immunity and infection. Int J Mol Sci. 2017;18:2197.
Rochman M, Wen T, Kotliar M, et al. Single‐cell RNA‐seq of human esophageal epithelium in homeostasis and allergic inflammation. JCI Insight. 2022;7:e159093.
Mazumder B, Sampath P, Seshadri V, Maitra RK, DiCorleto PE, Fox PL. Regulated release of L13a from the 60S ribosomal subunit as a mechanism of transcript‐specific translational control. Cell. 2003;115:187‐198.
Mazumder B, Li X, Barik S. Translation control: a multifaceted regulator of inflammatory response. J Immunol. 2010;184:3311‐3319.
Azouz NP, Ynga‐Durand MA, Caldwell JM, et al. The antiprotease SPINK7 serves as an inhibitory checkpoint for esophageal epithelial inflammatory responses. Sci Transl Med. 2018;10:eaap9736.
Min S, Shoda T, Wen T, Rothenberg ME. Diagnostic merits of eosinophilic esophagitis diagnostic panel from a single esophageal biopsy. J Allergy Clin Immunol. 2022;149:782‐787.e1.